Business Context and Reporting Period
This Form 8-K, dated November 21, 2022, reports a material definitive agreement between Graybug Vision, Inc. (the "Registrant") and CalciMedica, Inc. ("CalciMedica"). The filing details a proposed merger in which CalciMedica, a clinical-stage biopharmaceutical company, will become a wholly-owned subsidiary of Graybug. The transaction is structured as a tax-free reorganization.
Key Financial Metrics and Transaction Terms
- Valuation Basis: The transaction is based on a CalciMedica valuation of $100,000,000 and a Graybug valuation of $40,000,000.
- Ownership Structure: Post-merger, CalciMedica equity holders are expected to own approximately 71.4% of the combined company, while Graybug equity holders are expected to own approximately 28.6% (on a fully-diluted basis).
- Private Placement: CalciMedica entered into a Securities Purchase Agreement to sell approximately $10,340,662 of common stock to accredited investors immediately prior to the closing.
- Cash Condition: The closing is contingent on Graybug's net cash being no less than $18,000,000. The ownership percentages assume Graybug's net cash at closing is $25,000,000.
- Termination Fees: A fee of $1,000,000 may be payable by either party under certain termination scenarios. If Graybug terminates to pursue a superior transaction, a fee of $1,500,000 is payable to CalciMedica.
Material Changes and Corporate Actions
The filing announces a fundamental change in control and business focus. Key changes include:
- Management: A. Rachel Leheny is expected to serve as the Chief Executive Officer of the combined company.
- Board Composition: The new board will consist of seven directors: five designated by CalciMedica and two by Graybug.
- Stockholder Approvals: Graybug stockholders must approve a reverse stock split and the issuance of shares representing more than 20% of outstanding shares.
- Support Agreements: Support agreements representing approximately 45% of Graybug's outstanding shares and 86% of CalciMedica's outstanding shares have been executed to vote in favor of the merger.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the expected benefits and timing of the merger, which are subject to significant risks. Key contingencies and risks include:
- Closing Conditions: The transaction requires stockholder approval from both parties, regulatory approvals, and the satisfaction of net cash thresholds.
- Lock-Up Agreements: CalciMedica insiders and Graybug executives are subject to 180-day lock-up periods on their shares post-closing.
- Operational Risks: Risks include the ability to consummate the merger, potential delays, the impact of global financial markets or health epidemics, and the ability to obtain regulatory approval for CalciMedica's product candidate, Auxora.
- Expense Reimbursement: Graybug agreed to reimburse CalciMedica for up to $1,000,000 in expenses if the merger fails due to lack of stockholder approval, and up to $250,000 if terminated for a superior transaction.
Investor Verification Checklist
- Verify the final net cash position of Graybug at closing to confirm the $18,000,000 minimum threshold is met.
- Review the definitive proxy statement for details on the reverse stock split ratio and the exact exchange ratio for shares.
- Confirm the status of the Private Placement closing and the registration rights granted to purchasers.
- Monitor the regulatory approval status of CalciMedica's lead candidate, Auxora, as a key value driver.
- Check for any updates regarding the termination fees or changes in the board composition prior to the special meeting.